Ralph Goldman Zinner, MD

  • Director, Thoracic Oncology Program
REQUEST AN APPOINTMENT
Are you a physician?
Refer a Patient

Specialties

Conditions

About

Dr. Ralph Zinner is an experienced board-certified medical oncologist and accomplished scientific leader with more than 100 peer-reviewed publications. Dr. Zinner specializes in caring for patients with lung cancer and cancers of the head and neck.

Outside of the office, he loves meeting people throughout Kentucky and seeing the cities, towns and countryside with his wife, Jeri. He also often visits independent bookstores, enjoys world cinema, likes working in his garden, and is glad to be back weight training and jogging. 

Faculty Rank

  • Professor
  • fixes empty view field issue
    Ralph Zinner, MD - UK HealthCare

Training & Education

Degree

Georgetown University School of Medicine, Washington, District of Columbia

Residency

Thomas Jefferson University Hospital, Philadelphia, Pa.

Fellowship

Medical oncology fellowship, University of Texas MD Anderson Cancer Center, Houston

Certifications and Special Training

American Board of Internal Medicine Subspecialty Board of Medical Oncology

Research

Research Focus

Dr. Zinner’s work and research interests include:

  • Developing neoadjuvant and induction chemo-immune and molecularly targeted therapy regimens in surgery and radiation in the treatment of lung and head and neck cancer patients to reduce long-term morbidity and increase overall survival.
  • Working toward the development of a KRAS program in lung cancer, which Kentucky and the region are especially well-placed to lead nationally. 
  • Increasing the odds of long-term survival and well-being in newly diagnosed and recurrent advanced stage lung and head and neck cancer using novel combinations of existing or newer therapeutics.

Programs

Translational Oncology

Contact Information

800 Rose St., CC458
Lexington, KY 40536
United States

Email
mcch232@uky.edu

Publications

  1. Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes
    Thall PF, Nguyen HQ, Zinner RG. J R Stat Soc Ser C Appl Stat. 2017 Jan;66(1):201-224. doi: 10.1111/rssc.12162. Epub 2016 Jun 11. PubMed PMID: 28255183; PubMed Central PMCID: PMC5328131.
  2. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous
    Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366. PubMed PMID: 25371077; PubMed Central PMCID: PMC4276572.
  3. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer.
    Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 2014 Aug 1;120(15):2343-51. doi: 10.1002/cncr.28714. Epub 2014 Apr 18. PubMed PMID: 24752945; PubMed Central PMCID: PMC4140446.
  4. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426
    Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 1;28(4):614-9. doi: 10.1200/JCO.2009.23.6406. Epub 2009 Oct 19. PubMed PMID: 19841321; PubMed Central PMCID: PMC2815996.
  5. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
    Zinner RG, Barrett BL, Popova E, Damien P, Volgin AY, Gelovani JG, Lotan R, Tran HT, Pisano C, Mills GB, Mao L, Hong WK, Lippman SM, Miller JH. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther. 2009 Mar;8(3):521-32. doi: 10.1158/1535-7163.MCT-08-0937. Epub 2009 Mar 10. PubMed PMID: 19276160.